Company intelligence / Profile preview

Chimera Biotec

Bremen, Bremen, Germanychimera-biotec.com ↗

Ownership: Private
Development stage: Other

Overview

Chimera Biotec provides ultra-sensitive GLP/GCP-compliant bioanalytical support using proprietary and state-of-the-art immunoassay platforms. Their Imperacer® technology enables detection of proteins and antigens at sub-picogram per milliliter concentrations, supporting all phases of drug development from discovery to clinical trials. They have received industry recognition for their technological excellence.

Modalities: AntibodyDNA-antibody conjugateProtein
Industry: Contract Research Organization

Partnerships

AvTech Laboratories/Eurofins Scientific (ultra-high sensitive immunoassay technology partnership)

Beyond the preview

Go deeper on Chimera Biotec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chimera Biotec.

Explore the full profile